Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, MD PhD, Tadeusz Robak, MDPhD, Fatih Demirkan, MD, Osnat Bairey, MD, Carol Moreno, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Talha Munir, MBBS, Don A. Stevens, MD, Sandra Dai, PhD MS, Leo W. K. Cheung, PhD, Kevin Kwei, PhD, Indu Lal, MD, Emily Hsu, PhD, Thomas J. Kipps, MD PhD, Alessandra Tedeschi, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134437

Published: 2020

Journal Articles

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Adrian Wiestner, MD PhD, Paolo Ghia, MD PhD, John C. Byrd, MD, Inhye E Ahn, MD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Daniel Jones, MD PhD, Leo W. K. Cheung, PhD, Elizabeth Chong, PhD, Kevin Kwei, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jennifer A. Woyach, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134386

Published: 2020

Journal Articles

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

John N. Allan, MD, Tait Shanafelt, MD, Adrian Wiestner, MD PhD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Esteban Braggio, PhD, Emily Liu, MS, James P. Dean, MD PhD, Dominic Lai, PharmD, Inhye E. Ahn, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-134431

Published: 2020

Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134446

Published: 2020

Journal Articles

Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype

Blood (2019) 134 (Supplement_1): 4287.

https://doi.org/10.1182/blood-2019-126557

Published: 2019

Journal Articles

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Blood (2019) 134 (Supplement_1): 4296.

https://doi.org/10.1182/blood-2019-128470

Published: 2019

Journal Articles

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Carol Moreno, MD PhD, Richard Greil, MD, Fatih Demirkan, MD, Alessandra Tedeschi, MD, Bertrand Anz, MD, Loree Larratt, MD, Martin Simkovic, MD PhD, Olga Samoilova, MD, Jan Novak, MD PhD, Dina Ben-Yehuda, MD, Vladimir Strugov, MD, Devinder Gill, MD MRCP, FRCPath, John G. Gribben, Emily Hsu, PhD, Cathy Zhou, MS, Fong Clow, ScD, Danelle F. James, MD MAS, Lori Styles, MD, Ian W. Flinn, MD PhD

Blood (2018) 132 (Supplement 1): 691.

https://doi.org/10.1182/blood-2018-99-111370

Published: 2018

Journal Articles

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Blood (2018) 132 (Supplement 1): 5565.

https://doi.org/10.1182/blood-2018-99-111369

Published: 2018

Journal Articles

Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUO TM Study

Jennifer R. Brown, MD PhD, Ian W. Flinn, MD PhD, Matthew S. Davids, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Marco Montillo, MD, Zsolt Nagy, MD PhD, Julio Delgado, MD, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Ulrich Jaeger, MD, Paolo Ghia, MD PhD, Stephan Stilgenbauer, Carol Moreno, MD PhD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, Kam Sprott, PhD, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Florence Cymbalista, MD PhD

Blood (2018) 132 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2018-99-114251

Published: 2018

Journal Articles

Rituximab in Combination with Bendamustine or Chlorambucil for Treating Patients with Chronic Lymphocytic Leukemia: Interim Results of a Phase IIIb Study (MaBLe).

Veronique Leblond, Kamel Laribi, MD, Osman Ilhan, MD, Melih Aktan, Ali Unal, MD, Saad M B Rassam, MD, FRCP, FRCPath, Anna Schuh, MD, PhD, MRCP, FRCPath, Tom Widenius, MD, PhD, Peter Johansson, MD, PhD, Joao Raposo, Balkis Meddeb, Carol Moreno, MD, PhD, Stephan H.K. Oertel, MD, Anne-Sophie Michallet, MD, PhD

Blood (2012) 120 (21): 2744.

https://doi.org/10.1182/blood.V120.21.2744.2744

Published: 2012

Journal Articles

Expression Profile and Regulation of BAFF and APRIL Receptors in Chronic Lymphocytic Leukemia,

Gerardo Ferrer, Msc, Kate E Hodgson, MBBS, MRCP, FRCPath, Victor Ciria, Tycho Baumann, MD, Gael Roue, Dolors Colomer, MD. PhD, Emili Montserrat, MD. PhD, Carol Moreno, MD, PhD

Blood (2011) 118 (21): 3880.

https://doi.org/10.1182/blood.V118.21.3880.3880

Published: 2011

Journal Articles

Chronic Lymphocytic Leukemia Associated with Autoimmune Hemolytic Anemia Is Characterized by a Distinctive miRNA Signature,

Gerardo Ferrer, Msc, Alfons Navarro, PhD, Kate E Hodgson, MBBS, MRCP, FRCPath, Dolors Colomer, MD. PhD, Marta Aymerich, MD. PhD, Tycho Baumann, MD, Arturo Pereira, MD. PhD, Mariano Monzó, MD, PhD, Carol Moreno, MD, PhD, Emili Montserrat, MD. PhD

Blood (2011) 118 (21): 3897.

https://doi.org/10.1182/blood.V118.21.3897.3897

Published: 2011

Journal Articles

B Cell Stimulation through BCR and CD40 Modulates the Response of Chronic Lymphocytic Leukemia Cells to BAFF and APRIL.

Gerardo Ferrer, Kate E Hodgson, MD, Victor Ciria, Gael Roue, Dolors Colomer, MD, PhD, Emili Montserrat, MD, Carol Moreno, MD, PhD

Blood (2010) 116 (21): 1361.

https://doi.org/10.1182/blood.V116.21.1361.1361

Published: 2010

Journal Articles

Autoimmune Cytopenias In Chronic Lymphocytic Leukemia: Prevalence, Clinical Correlations, and Prognostic Significance In a Large, Unselected Series of Patients From a Single Institution

Carol Moreno, MD, PhD, Kate E Hodgson, MD, Gerardo Ferrer, Montse Elena, MD, Xavier Filella, MD, Arturo Pereira, MD, Tycho Baumann, MD, Emili Montserrat, MD

Blood (2010) 116 (21): 1366.

https://doi.org/10.1182/blood.V116.21.1366.1366

Published: 2010

Journal Articles

Immune Status In Patients with Chronic Lymphocytic Leukemia and Sustained Complete Remission: A Multiparametric Analysis

Kate E Hodgson, MD, Gerardo Ferrer, Carmen Martinez, MD, Manel Juan, Tycho Baumann, MD, Montserrat Rovira, MD, Marta Aymerich, Laura Carretero, Francesc Bosch, MD, Alvaro Urbano, MD, Emili Montserrat, MD, Carol Moreno, MD, PhD

Blood (2010) 116 (21): 1389.

https://doi.org/10.1182/blood.V116.21.1389.1389

Published: 2010

Journal Articles

Changes in the Natural History, Treatment Modalities, and Survival Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) from 1980 to 2008. The Hospital Clinic of Barcelona Experience

Pau Abrisqueta, MD, Francesc Bosch, MD, PhD, Marta Aymerich, MD, PhD, Eva Gine, MD, Carol Moreno, MD, PhD, Maria Rozman, MD, PhD, Neus Villamor, MD, PhD, Elias Campo, MD, PhD, Ciril Rozman, MD, PhD, Emili Montserrat, MD, PhD

Blood (2008) 112 (11): 48.

https://doi.org/10.1182/blood.V112.11.48.48

Published: 2008

NARROW

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUO TM Study

Rituximab in Combination with Bendamustine or Chlorambucil for Treating Patients with Chronic Lymphocytic Leukemia: Interim Results of a Phase IIIb Study (MaBLe).

Expression Profile and Regulation of BAFF and APRIL Receptors in Chronic Lymphocytic Leukemia,

Chronic Lymphocytic Leukemia Associated with Autoimmune Hemolytic Anemia Is Characterized by a Distinctive miRNA Signature,

B Cell Stimulation through BCR and CD40 Modulates the Response of Chronic Lymphocytic Leukemia Cells to BAFF and APRIL.

Autoimmune Cytopenias In Chronic Lymphocytic Leukemia: Prevalence, Clinical Correlations, and Prognostic Significance In a Large, Unselected Series of Patients From a Single Institution

Immune Status In Patients with Chronic Lymphocytic Leukemia and Sustained Complete Remission: A Multiparametric Analysis

Changes in the Natural History, Treatment Modalities, and Survival Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) from 1980 to 2008. The Hospital Clinic of Barcelona Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only